
|Articles|January 24, 2005
BREAKING NEWS...
The black eye the FDA received recently over its handling of Vioxx (rofecoxib, Merck) and antidepressants hasn't slowed the agency's new drug approval rate for 2004. It cleared 31 new molecular entities (NMEs) last year, up from 21 in 2003.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
American Pharmacists Month: Pharmacist Barriers, Expansion of Scope Since the COVID-19 Pandemic
2
Pass-Through Rebate Law Uncovering New PBM Tactics, Entities | NCPA 2025
3
Community Pharmacies Need to Better Prioritize Whole-Person Health Care | NCPA 2025
4
Automation Helps Pharmacies Maximize Revenue, Improve Patient Care | NCPA 2025
5


























































































































































